Combined effects of lonidamine and tamoxifen in human breast cancer cell lines

D. Gornati, N. Zaffaroni, L. Orlandi, G. Di Fronzo, R. Silvestrini

Research output: Contribution to journalArticle

Abstract

The antiproliferative activity of lonidamine, alone or in combination with the antiestrogen tamoxifen, was studied on estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines. Lonidamine by itself induced an appreciable cytotoxic effect on all five cell lines, with 50% inhibitory concentrations (IC50) ranging from 19.5 to 54 μM. The combination of lonidamine and tamoxifen, simultaneously administered or in sequence, provided additive effects on the estrogen receptor-negative MCF/DX cell line and a sub-additive interaction in the estrogen receptor-positive MCF7 cells. The negative interference between the two drugs could be ascribed to the marked reduction induced by lonidamine in the expression of estrogen receptor in the MCF7 cells.

Original languageEnglish
Pages (from-to)993-996
Number of pages4
JournalInternational Journal of Oncology
Volume6
Issue number5
Publication statusPublished - 1995

Fingerprint

Tamoxifen
Estrogen Receptors
Breast Neoplasms
Cell Line
MCF-7 Cells
Inhibitory Concentration 50
Estrogen Receptor Modulators
lonidamine
Pharmaceutical Preparations

Keywords

  • Breast cancer cell lines
  • Estrogen receptor
  • Lonidamine
  • Progesterone receptor
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gornati, D., Zaffaroni, N., Orlandi, L., Di Fronzo, G., & Silvestrini, R. (1995). Combined effects of lonidamine and tamoxifen in human breast cancer cell lines. International Journal of Oncology, 6(5), 993-996.

Combined effects of lonidamine and tamoxifen in human breast cancer cell lines. / Gornati, D.; Zaffaroni, N.; Orlandi, L.; Di Fronzo, G.; Silvestrini, R.

In: International Journal of Oncology, Vol. 6, No. 5, 1995, p. 993-996.

Research output: Contribution to journalArticle

Gornati, D, Zaffaroni, N, Orlandi, L, Di Fronzo, G & Silvestrini, R 1995, 'Combined effects of lonidamine and tamoxifen in human breast cancer cell lines', International Journal of Oncology, vol. 6, no. 5, pp. 993-996.
Gornati, D. ; Zaffaroni, N. ; Orlandi, L. ; Di Fronzo, G. ; Silvestrini, R. / Combined effects of lonidamine and tamoxifen in human breast cancer cell lines. In: International Journal of Oncology. 1995 ; Vol. 6, No. 5. pp. 993-996.
@article{38e6ae858c254ff299d3612221fb971c,
title = "Combined effects of lonidamine and tamoxifen in human breast cancer cell lines",
abstract = "The antiproliferative activity of lonidamine, alone or in combination with the antiestrogen tamoxifen, was studied on estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines. Lonidamine by itself induced an appreciable cytotoxic effect on all five cell lines, with 50{\%} inhibitory concentrations (IC50) ranging from 19.5 to 54 μM. The combination of lonidamine and tamoxifen, simultaneously administered or in sequence, provided additive effects on the estrogen receptor-negative MCF/DX cell line and a sub-additive interaction in the estrogen receptor-positive MCF7 cells. The negative interference between the two drugs could be ascribed to the marked reduction induced by lonidamine in the expression of estrogen receptor in the MCF7 cells.",
keywords = "Breast cancer cell lines, Estrogen receptor, Lonidamine, Progesterone receptor, Tamoxifen",
author = "D. Gornati and N. Zaffaroni and L. Orlandi and {Di Fronzo}, G. and R. Silvestrini",
year = "1995",
language = "English",
volume = "6",
pages = "993--996",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Combined effects of lonidamine and tamoxifen in human breast cancer cell lines

AU - Gornati, D.

AU - Zaffaroni, N.

AU - Orlandi, L.

AU - Di Fronzo, G.

AU - Silvestrini, R.

PY - 1995

Y1 - 1995

N2 - The antiproliferative activity of lonidamine, alone or in combination with the antiestrogen tamoxifen, was studied on estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines. Lonidamine by itself induced an appreciable cytotoxic effect on all five cell lines, with 50% inhibitory concentrations (IC50) ranging from 19.5 to 54 μM. The combination of lonidamine and tamoxifen, simultaneously administered or in sequence, provided additive effects on the estrogen receptor-negative MCF/DX cell line and a sub-additive interaction in the estrogen receptor-positive MCF7 cells. The negative interference between the two drugs could be ascribed to the marked reduction induced by lonidamine in the expression of estrogen receptor in the MCF7 cells.

AB - The antiproliferative activity of lonidamine, alone or in combination with the antiestrogen tamoxifen, was studied on estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines. Lonidamine by itself induced an appreciable cytotoxic effect on all five cell lines, with 50% inhibitory concentrations (IC50) ranging from 19.5 to 54 μM. The combination of lonidamine and tamoxifen, simultaneously administered or in sequence, provided additive effects on the estrogen receptor-negative MCF/DX cell line and a sub-additive interaction in the estrogen receptor-positive MCF7 cells. The negative interference between the two drugs could be ascribed to the marked reduction induced by lonidamine in the expression of estrogen receptor in the MCF7 cells.

KW - Breast cancer cell lines

KW - Estrogen receptor

KW - Lonidamine

KW - Progesterone receptor

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0028965827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028965827&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 993

EP - 996

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -